ReviewDiscover nano2026
A perspective on magnetic ionic liquids as multifunctional platforms for drug delivery and biomedical applications.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The demand for advanced field-responsive materials has positioned magnetic ionic liquids (MILs) as a transformative class of tunable fluids that bridge materials science and biomedicine. Initially valued for magnetically induced behaviors, MILs excel in surface activity, solubility enhancement (up to 39,000-fold for poorly soluble drugs), colloidal stabilization, and polymer-surfactant interactions at interfaces. Recent computational advances, Density Functional Theory (DFT) for electronic structures and ion reactivity, alongside Molecular Dynamics (MD) simulations, predict properties across timescales, enabling design-driven synthesis of low-viscosity, high-magnetic-moment formulations with thermal stability to 345 °C. In biomedicine, MILs promise targeted drug delivery, NIR-fluorescent theranostics, and dual-mode MRI contrast via paramagnetic chelates, with 2025 breakthroughs in magnet-guided tumor nanocomplexes outperforming traditional nanoparticles. Their significance lies in their use as stimuli-responsive platforms for oncology, neurology, and antimicrobial therapies, thereby enhancing bioavailability and enabling green, recyclable pharmaceutical processes. Yet, critical gaps persist. Fe-based MILs suffer from hydrolysis and reproducibility issues, while Co/Mn variants raise toxicity concerns, limiting biocompatibility, in vivo biodistribution studies, and pharmacokinetics data. Scalability hurdles, such as high costs, non-standardized characterization, and inadequate models for field effects on transport, hinder clinical translation. This perspective critically reflects on the evolution of MIL research, integrating experimental and computational advances, and underscores the need for design-driven synthesis, standardised characterisation, and application-oriented strategies. By highlighting achievements, addressing key challenges, and mapping future directions, we aim to stimulate cross-disciplinary dialogue and accelerate the translation of MILs into next-generation technological and biomedical platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.